Joplin Globe18h
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...
Business Insider23h
Exact Sciences to present abstracts on multi-cancer early detection test
Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...
Exact Sciences Announces Third-Quarter 2024 Results
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
Investing15d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product. The analyst ...
Investing15d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.
Pharmabiz15d
Exact Sciences presents multiple studies at ACG 2024; demonstrating leadership in noninvasive colorectal cancer screening and patient engagement
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced the company presenting modeling data evaluating the simulated benefit and burden of established CRC ...